MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Treating Female Urinary Incontinence

Back to obgyn news Blogs list Cancer blog  


Subscribe To Obgyn News RSS Feed  RSS content feed What is RSS feed?

Treating Female Urinary Incontinence

Treating Female Urinary Incontinence
A minimally invasive device for treating recurrent stress urinary incontinence in women has been shown to be safe and effective in early clinical trials and is now under review by the U.S. Food and Drug Administration (FDA), says Emory University School of Medicine urologist and trial co-principal investigator Niall Galloway, MD.

Preliminary results from the North American Adjustable Continence Therapy (ACT) clinical study group will be presented today at the annual meeting of the American Urological Association convened in Anaheim, Calif.

The first phase of the multi-center ACT clinical trial, which included Emory, launched in December 2001 and will conclude in June. It tested the device in 160 women diagnosed with stress urinary incontinence who failed to respond to prior therapys.

During the outpatient procedure, which lasts 20-30 minutes, two adjustable balloons are implanted on each side of a patient's urethra. The ACT clinical trial patients on average reported significant continence improvement one year after undergoing therapy. Complications were commonly mild.

"The ACT device spells hope for millions of women dealing with incontinence, especially those who've experienced severe weakness of the urethra muscles," says Dr. Galloway. "Follow up is needed, but the results we have thus far are promising".

It's estimated that 13 million people in the U.S. suffer from incontinence, or loss of bladder or bowel control. At least 85 percent of sufferers are women.

A broad range of conditions and disorders can cause incontinence, including birth defects, pelvic surgery, injuries to the pelvic region or to the spinal cord, neurological diseases, multiple sclerosis, poliomyelitis, infection and degenerative changes linked to aging. It also can occur as a result of pregnancy or childbirth.

The ACT device developed by Uromedica, Inc. may appeal to women seeking a minimally invasive treatment with a shorter recovery time than offered by traditional incontinence surgical therapys, Dr. Galloway says. With ACT, there are no abdominal or vaginal incisions. The balloons can be adjusted post-operatively as needed, eliminating the risk of overtreatment or undertreatment, challenges posed by some existing therapies, he added. The ACT is also reversible. A similar device called ProACT is being tested in men with stress urinary incontinence after prostate surgery.


Posted by: Emily    Source




Did you know?
A minimally invasive device for treating recurrent stress urinary incontinence in women has been shown to be safe and effective in early clinical trials and is now under review by the U.S. Food and Drug Administration (FDA), says Emory University School of Medicine urologist and trial co-principal investigator Niall Galloway, MD.

Medicineworld.org: Treating Female Urinary Incontinence

Asthma| Hypertension| Medicine Main| Diab french| Diabetes drug info| DruginfoFrench| Type2 diabetes| Create a dust free bedroom| Allergy statistics| Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.